With RSD to Turkey – one of the most popular study-travel destinations worldwide
11.7.2024 10:53:41 CEST | news aktuell GmbH | Press release
Unique antique ruins and expansive beaches by the glittering sea, picturesque old towns and great hospitality: This and much more is what Turkey offers. A truly wonderful travel destination. And from the beginning, one of the most important pillars in the broad portfolio of study tours offered by RSD Travel Ltd..

Despite the Corona crisis, demand for Turkish tours has surged once again due to their high-quality offerings and value for money. Over half a million RSD clients have already enjoyed memorable holidays, discovering Turkey's natural and cultural diversity while staying in star-rated hotels – sometimes even with private beach.
RSD owes its high customer satisfaction in Turkey to its professional team, who know the country by heart. There is a lot of praise for this - for example from Professor Nevzat Cevik, one of the most well-known excavation directors of ancient sites in the country: "Thank you for making our well-preserved historical treasures, our breathtaking landscapes and our fascinating history come alive for a broad, interested educated class!". The 15-day Cappadocia 5-star trip, for instance, allows guests to witness the incredible Monk's Valley, a UNESCO World Heritage Site, and explore the vibrant Antalya along the Mediterranean.
During the two-week exclusive Lycia trip, guests can traverse the important ruins of Ephesus, marvel at Pamukkale's unique limestone terraces, and the Temple of Artemis - one of the seven wonders of the ancient world. Through an Istanbul & Aegean combo package, visitors can explore the grandeur of Istanbul, including the world-renowned Hagia Sophia, the old town - a UNESCO World Heritage Site, and the luxurious Topkapi Palace, once the government seat of the Ottoman Sultans.
Towcester
Phone: + 44 20 3514 35 43
e-mail: info@rsd-travel.co.uk
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:52:44 CEST | Press release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
Polarise Launches Sovereign AI Cloud at NVIDIA GTC Berlin, Delivering Enterprise AI From Data Center to Application22.10.2026 10:00:00 CEST | Press release
With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud
Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release
New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.
agineo expands partnership with ServiceNow, launches AI Control Tower as a Service20.10.2026 13:06:01 CEST | Press release
New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom